Administration of influenza vaccines to egg allergic recipients: A practice parameter update 2017.

Reprints: Matthew Greenhawt, MD, MBA, MSc, Section of Allergy and Clinical Immunology, Children’s Hospital Colorado, University of Colorado School of Medicine, 13123 East 16th Avenue, Box 518, Anschutz Medical Campus, Aurora, CO 80045; E-mail: [email protected]. Disclosures: The following is a summary of interests disclosed onWork Groupmembers’ conflict of interest disclosure statements (not including information concerning family member interests). Completed conflict of interest disclosure statements are available on request and are available at https://www.allergyparameters.org/. Conflicts of interest disclosure statements for Joint Task Force on Practice Parameters (JTFPP) are also available there. Dr Greenhawt is supported by grant K08HS024599 from the Agency for Healthcare Quality and Research; is an expert panel and coordinating committeemember of the National Institute of Allergy and Infectious Diseases–sponsored Guidelines for Peanut Allergy Prevention; has served as a consultant for theCanadianTransportationAgency andAimmuneTherapeutics; is amember of physician/medical advisory boards forAimmune, Nutricia, Kaleo Pharmaceutical, Intrommune, Nestle, and Monsanto; is a member of the scientific advisory council for the National Peanut Board; has received honorarium for lectures from Thermo Fisher, the Western/Pennsylvania/Aspen/New York/Swineford allergy societies, the ACAAI, and the EAACI; and is a member of the JTFPP. Dr Turner is in receipt of a Clinician Scientist Award funded by the UKMedical Research Council (MR/K010468/1). He has received funding from the UK Departments of Health policy research program (National Vaccine Evaluation Consortium); the European Union’s Seventh Framework Program for research, technological development, and demonstration (grant agreement 312147, iFAAMproject); End Allergies Together, a 501(c)(3) nonprofit organization; and theNational Institute for Health Research (NIHR) Biomedical Research Centre based at Imperial College Healthcare National Health Service (NHS) Trust and Imperial College London. No other disclosures were reported. The JTFPP recognizes that experts in a field are likely to have interests that could come into conflict with development of a completely unbiased and objective practice parameter. To take advantage of that expertise, a process has been developed to prevent potential conflicts from influencing the final document in a negative way. At the workgroup level, members who have a potential conflict of interest either do not participate in discussions concerning topics related to the potential conflict or, if they do write a section on that topic, the workgroup completely rewrites it without their involvement to remove potential bias. In addition, the entire document is reviewed by the JTFPP and any apparent bias is removed at that level. Finally, the practice parameter is sent for review by invited reviewers and anyone with an interest in the topic by posting the document on the websites of the ACAAI and the AAAAI. The JTFPP is a 12-member taskforce consisting of 6 representatives assigned by the AAAAI and 6 by the ACAAI. This taskforce oversees the development of practice parameters, selects theworkgroup chair(s), and reviews drafts of the parameters for accuracy, practicality, clarity, and broad utility of the recommendations for clinical practice. Disclaimer: The American Academy of Allergy, Asthma, and Immunology (AAAAI) and the American College of Allergy, Asthma, and Immunology (ACAAI) have jointly accepted responsibility for establishing Influenza Vaccine: A Practice Parameter Update 2017. This is a complete and comprehensive document at the current time. The medical environment is a changing environment, and not all recommendations will be appropriate for all patients. Because this document incorporated the efforts of many participants, no single individual, including those who served on the Joint Task Force on Practice Parameters, is authorized to provide an official AAAAI or ACAAI interpretation of these practice parameters. Any request for information about or an interpretation of these practice parameters by the AAAAI or ACAAI should be directed to the executive offices of the AAAAI and/or the ACAAI. These parameters are not designed for use by pharmaceutical companies in drug promotion. The views expressed here are those of the author(s) and not necessarily those of the NHS, NIHR, or the Department of Health. Published parameters are available at https://www.allergyparameters.org/. Contributors: The Joint Task Force on Practice Parameters hasmade a concerted effort to acknowledge all contributors to this parameter. If any contributors have been excluded inadvertently, the Task Force will ensure that appropriate recognition of such contributions is made subsequently. Workgroup Chair: Matthew Greenhawt, MD, MBA, MSc, Department of Pediatrics, Children’s Hospital of Colorado, Section of Allergy and Immunology, University of Colorado School of Medicine, Aurora, Colorado. Joint Task Force on Practice Parameter Members: David I. Bernstein, MD, Department of Clinical Medicine and Environmental Health, Division of Immunology, Allergy, and Rheumatology, University of Cincinnati College of Medicine, Cincinnati, Ohio; Joann Blessing-Moore, MD, Department of Immunology, Stanford University Medical Center, Palo Alto, California; Chitra Dinakar,MD, Stanford University School of Medicine, Allergy & Asthma Clinical Chief, StanfordHealth Care, Division of Pulmonary and Critical CareMedicine, Department of Medicine, Stanford University, Stanford, California; Matthew Greenhawt, MD, MBA, MSc, Department of Pediatrics, Children’s Hospital of Colorado, Section of Allergy and Immunology, University of Colorado School of Medicine, Aurora, Colorado; Caroline Horner, MD, Department of Pediatrics, Division of Allergy, Immunology and Pulmonary Medicine, Washington University School of Medicine, St Louis, Missouri; David A. Khan, MD, Department of Internal Medicine, Division of Allergy and Immunology, University of Texas Southwestern Medical Center, Dallas, Texas; David M. Lang, MD, Department of Medicine, Department of Allergy and Clinical Immunology, and the Allergy and Immunology Fellowship Training Program, Cleveland Clinic Foundation, Cleveland, Ohio; John Oppenheimer, MD, Department of Internal Medicine, New Jersey Medical School, Morristown, New Jersey; Jay M. Portnoy, MD, Section of Allergy, Asthma & Immunology, The Children’s Mercy Hospital, University of Missouri-Kansas City School of Medicine, Kansas City, Missouri; Christopher C. Randolph, Center for Allergy, Asthma and Immunology, Yale Hospitals, Waterbury, Connecticut; Matthew Rank, MD, Division of Allergy, Asthma, and Clinical Immunology,Mayo Clinic School ofMedicine, Scottsdale, Arizona; DanaWallace,MD, Department ofMedicine, Nova SoutheasternUniversity, Davie, Florida. ParameterWorkgroupMembers:MatthewGreenhawt,MD,MBA,MSc, Department of Pediatrics, Children’s Hospital of Colorado, Section of Allergy and Immunology, University of Colorado School of Medicine, Aurora, Colorado; JohnM. Kelso, MD, Division of Allergy, Asthma and Immunology, Scripps Clinic, San Diego, California; Paul J. Turner, BM, BCh, FRACP, PhD, Imperial College London and Imperial CollegeHealthcareNHS Trust & Royal Brompton&HarefieldNHS Foundation Trust, London, United Kingdom, andDepartment of Paediatrics, University of Sydney, Sydney, Australia. Invited SocietyReviewers: RaghavaCharya,MD, Bethesda,Maryland;KathrynConvers,MD,Valrico, Florida; SunitaKanumury, MD, Denville, New Jersey; Sangeetha Kodoth, MD, Knoxville, Tennessee; James T. Li, MD, Rochester, Minnesota; and Jim Parkerson, MD, Fort Wayne, Indiana.